Avalo Therapuetics (AVTX) – Press Releases
-
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
-
Avalo Reports 2023 Financial Results and Provides Business Updates
-
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
-
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
-
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
-
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
-
Avalo Completes Divestiture of AVTX-800 Series
-
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
-
Avalo Enters into Agreement to Divest AVTX-800 Series
-
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
-
Avalo to Participate in SVB Securities Therapeutics Forum
-
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
-
Avalo to Present at the Jefferies Healthcare Conference
-
Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
-
Avalo to Present at ATS 2023 Respiratory Innovation Summit
-
Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
-
Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates
-
Avalo Reports 2022 Financial Results and Provides Business Updates
-
Avalo Reports 2022 Financial Results and Provides Business Updates
-
Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference
-
Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference
-
Origin Materials and Avantium to Accelerate the Mass Production of FDCA and PEF for Advanced Chemicals and Plastics
-
Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants
-
Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants
-
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants
-
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants
-
Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma
-
Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma
-
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates
-
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates
-
Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million
-
Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million
-
Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage
-
Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage
-
Avalo to Present at the H.C. Wainwright Global Investment Conference
-
Avalo to Present at the H.C. Wainwright Global Investment Conference
-
Avalo Therapeutics Announces Board Changes
-
Avalo Therapeutics Announces Board Changes
-
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
-
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
-
Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)
-
Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)
-
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
-
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
-
Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split
-
Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split
-
Avalo to Present at the 2022 Jefferies Healthcare Conference
-
Avalo to Present at the 2022 Jefferies Healthcare Conference
-
Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)
Back to AVTX Stock Lookup
